Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bluebird Bio
(NQ:
BLUE
)
0.9401
+0.0001 (+0.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bluebird Bio
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
20
21
Next >
US Stocks Open Higher, Dow Jumps Over 200 Points
March 29, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining over 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.72% to 32,628.42 while the NASDAQ rose 1.33%...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 29, 2023
Via
Benzinga
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
March 29, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Earnings Preview
March 28, 2023
Via
Benzinga
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
March 22, 2023
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India.
Via
Benzinga
Analyst Expectations for bluebird bio's Future
March 07, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About bluebird bio
January 24, 2023
Via
Benzinga
Why Bluebird Bio (BLUE) Stock Is Getting Hammered
January 18, 2023
Bluebird Bio Inc (NASDAQ: BLUE) shares are trading lower by 10.0% to $6.55 Wednesday morning after the company announced a proposed public offering of common stock.
Via
Benzinga
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
March 10, 2023
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
March 07, 2023
Via
Benzinga
1 Beaten-Down Stock That Has a Lot to Prove in 2023
February 08, 2023
This biotech looks like a high-risk, high-reward play.
Via
The Motley Fool
Skechers To Rally 40%? Here Are 10 Other Analyst Forecasts For Monday
January 23, 2023
Credit Suisse raised the price target for Exelon Corporation (NASDAQ: EXC) from $42 to $46. Credit Suisse analyst Nicholas Campanella maintained an Outperform rating. Exelon shares fell 0.1% to $42.32...
Via
Benzinga
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
January 22, 2023
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
Via
The Motley Fool
Tesla, Amazon, bluebird, Netflix, Discover Financial: Why These 5 Stocks Are Drawing Investors' Attention Today
January 18, 2023
Major Wall Street indices closed over 1.2% lower on Wednesday, dragged by renewed concerns of a recession as U.S. retail sales declined by the most in 12 months, down 1.1% in December as against...
Via
Benzinga
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
January 18, 2023
From
bluebird bio, Inc.
Via
Business Wire
PNC Financial, bluebird bio And Other Big Stocks Moving Lower On Wednesday
January 18, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 300 points on Wednesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Why Is Zomedica (ZOM) Stock Up Today?
January 18, 2023
Zomedica (ZOM) stock is on the rise Wednesday after the company signed a strategic restructuring agreement with Qorvo Biotechnologies.
Via
InvestorPlace
Moderna (MRNA) Stock Pops on RSV Vaccine Trial Results
January 18, 2023
Moderna (MRNA) stock is on the move Wednesday alongside positive results from its latest Phase 3 mRNA-1345 vaccine trial.
Via
InvestorPlace
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
January 18, 2023
The Nasdaq looked poised for modest gains once again on Wednesday.
Via
The Motley Fool
Why is Bluebird Bio (BLUE) Stock Down 9% Today?
January 18, 2023
Bluebird Bio (BLUE) stock is slipping on Wednesday after the biotechnology company announced a proposed public offering.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 18, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 18, 2023
We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning!
Via
InvestorPlace
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
January 18, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023
From
bluebird bio, Inc.
Via
Business Wire
2 Stocks That Could Double Your Money in 2023
January 07, 2023
These biotechs could crush the market, but there is more to the story.
Via
The Motley Fool
bluebird bio Sells Second Priority Review Voucher for $95 Million
January 06, 2023
From
bluebird bio, Inc.
Via
Business Wire
Newly Approved Drugs In US Command Over $200,000 On An Average
January 05, 2023
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003.
Via
Benzinga
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
January 03, 2023
From
bluebird bio, Inc.
Via
Business Wire
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
December 30, 2022
Both stocks have fallen brutally this year, but only one has a chance to recover soon.
Via
The Motley Fool
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.